Navigation Links
OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
Date:2/11/2009

ROCKVILLE, Md., Feb. 11 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene") today announced it has raised an additional $6.5 million in a private equity financing. With this financing, OriGene completed the acquisition of the assets of privately held Shenzhen P&A Biotech, a manufacturer and provider of monoclonal antibodies (mAb) to the research community. With this acquisition OriGene completes the establishment of its technology center to develop genome-wide monoclonal antibodies to all human proteins.

Over the last ten years OriGene has developed the capacity to produce thousands of human full-length proteins from human cells. These human cell produced human proteins are ideal antigens for high throughput monoclonal antibody production. During the last two years, OriGene also has developed a genome wide collection of antigen standards and over 100,000 tissue samples that are ideal tools for high quality antibody validation. With OriGene's China monoclonal antibody production capacity and these unique genome-wide resources OriGene believes it can produce several thousand high quality monoclonal antibodies per year.

This genome-wide mAb production capacity is available to all commercial and academic partners with a long-term goal to providing high quality monoclonal antibodies for every single human gene.

About OriGene

OriGene Technologies, Inc. is a gene centric life sciences tool company dedicated to support academic, pharmaceutical and biotech companies for research and drug discovery. Our flagship products are the world's largest cDNA and shRNA clone collections. Other key products include over 100,000 highly validated human tissues through its wholly owned subsidiary Cytomyx LLC., and its tissue derivative products tissue qPCR arrays for biomarker discovery and validation. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards
'/>"/>

SOURCE OriGene Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
2. New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers
3. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
4. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
5. Cascades Technologies, Inc. and SAIC Team on $19 Million Contract with National Institutes of Health
6. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
7. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
8. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
9. Wound Management Technologies, Inc. Announces a Published Case Study
10. Cascades Technologies, Inc. Chosen to Deliver IT Support on a DoD Blast Injury Research Program
11. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...e and Introduces Q1 2008 Guidance, FRAZER, Pa., F...ed 2007 sales of $1.727 billion, compared to sales...,s previously issued,guidance. Basic loss per comm...ng the previously announced settlement reserve, am...adjusted income per common share for the,full year...
... Technology Leadership, INDIANAPOLIS, Feb. 12 Th...wholly owned subsidiary of The Dow Chemical,Compan...ade to investors,earlier today by Jerome Peribere,...as speaking at the Goldman Sachs Agricultural Chem...rced Dow AgroSciences,technology-based strategy of...
...Corporation (NYSE: CBM ) announced that it will r... results on Thursday, February 14, 2008 after,mark.../prnh/20000613/CAMBREXLOGO ), The Company will h...r,and full year 2007 financial results., ...s Conference Call, When: Friday, Februa...
Other Biology Technology:Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 2Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 3Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 4Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 5Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 6Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 7Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 8Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 9Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 10Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 11Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 12Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 13Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 14Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 15Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 16Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 17Dow AgroSciences' Success Presented to Wall Street 2
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)Spanish researchers have measured CO2 levels for the past three years in the troposphere (lower atmosphere) over a sparsely inhabited rural area near Valladolid. The results, which are the first of th
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2Grooving down the helix 2Grooving down the helix 3Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 1Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 2Benefit of glinides is not proven 49380 1Benefit of glinides is not proven 49380 2Benefit of glinides is not proven 49380 37th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 17th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 27th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 3
...e investigating exactly how chemotherapy drugs kil...s and test the effectiveness of safer new agents. ...versity of Manchester,s Faculty of Life Sciences h...ti-mitotic drugs, which are used extensively for b...f drugs, which includes the agent taxol, has been ...
...imate change, researchers at BBSRC-supported Rotha...amaging aphids the peach-potato aphid (Myzus pers...er for every 1C rise in mean temperature for Janua...hid was caught on 25 April, which is almost four w...eported in BBSRC Business, the quarterly researc...
...erated in health care, computational biology, home... massive and unstructured data sets has proven cum...known as data and visual analytics is helping sift... put together individual pieces of a picture. , T...five-year grant to lead and coordinate a new initi...
Other Biology News:How chemo kills tumors: research to reduce side effects 2How chemo kills tumors: research to reduce side effects 3Aphids are sentinels of climate change 2Grant supports emerging field of massive data analysis and visual analytics 2Grant supports emerging field of massive data analysis and visual analytics 3Grant supports emerging field of massive data analysis and visual analytics 4
Mouse Anti-Yersinia pestis F1 antigen Monoclonal Antibody, Unconjugated, Clone 1.F.1 from Abcam
Rabbit Anti-L Kynurenine Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-P5 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Drosophila Melanogaster Achaete protein Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Biology Products: